U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13NO3S2.C15H12NO3S2.C5H14NO
Molecular Weight 741.96
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of DIEPALRESTAT CHOLINE

SMILES

C[N+](C)(C)CCO.CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O.CC(=C/C3=CC=CC=C3)\C=C4/SC(=S)N(CC([O-])=O)C4=O

InChI

InChIKey=WKSNHZZSMLFYFI-UROVXFGGSA-M
InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;

HIDE SMILES / InChI

Molecular Formula C5H13NO
Molecular Weight 103.1628
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 2
Optical Activity NONE

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P15121
Gene ID: 231.0
Gene Symbol: AKR1B1
Target Organism: Homo sapiens (Human)
0.28 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
KINEDAK

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
1998 Jun
Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy.
2001 Jun
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
2011 Aug 15
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

50 mg, 3 times/day
Route of Administration: Oral
In Vitro Use Guide
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:36:42 UTC 2023
Edited
by admin
on Sat Dec 16 10:36:42 UTC 2023
Record UNII
16AHE7410O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIEPALRESTAT CHOLINE
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, (5Z)-5-((2E)-2-METHYL-3-PHENYL-2-PROPEN-1-YLIDENE)-4-OXO-2-THIOXO-3-THIAZOLIDINEACETATE, (5Z)-5-((2E)-2-METHYL-3-PHENYL-2-PROPEN-1-YLIDENE)-4-OXO-2-THIOXO-3-THIAZOLIDINEACETATE (1:1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
117587644
Created by admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
PRIMARY
CAS
1665300-21-9
Created by admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
PRIMARY
FDA UNII
16AHE7410O
Created by admin on Sat Dec 16 10:36:42 UTC 2023 , Edited by admin on Sat Dec 16 10:36:42 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY